Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-07-07
2009-12-01
Wilson, James O (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S230000, C544S350000
Reexamination Certificate
active
07625899
ABSTRACT:
Disclosed are pyridodihydropyrazinone compounds, processes for preparing them and their use as pharmaceutical compositions. The compounds according to the invention correspond to general formula (I),while the groups L, R1, R2, R3, R4and R5may have the meanings given in the claims and specification.
REFERENCES:
patent: 4957922 (1990-09-01), Lammens et al.
patent: 5167949 (1992-12-01), Ferrand et al.
patent: 5424311 (1995-06-01), Billhardt-Troughton et al.
patent: 5698556 (1997-12-01), Chan
patent: 6174895 (2001-01-01), Kleinman
patent: 6605255 (2003-08-01), Kroll et al.
patent: 6806272 (2004-10-01), Bauer et al.
patent: 7238807 (2007-07-01), Duran et al.
patent: 7241889 (2007-07-01), Hoffmann et al.
patent: 7332491 (2008-02-01), Grauert et al.
patent: 7371753 (2008-05-01), Stadtmueller et al.
patent: 2002/0183292 (2002-12-01), Pairet et al.
patent: 2002/0183293 (2002-12-01), Banerjee et al.
patent: 2003/0130286 (2003-07-01), Denny et al.
patent: 2004/0029885 (2004-02-01), Bauer et al.
patent: 2004/0147524 (2004-07-01), Bauer et al.
patent: 2004/0176380 (2004-09-01), Hoffmann et al.
patent: 2005/0014760 (2005-01-01), Hoffmann et al.
patent: 2005/0014761 (2005-01-01), Hoffmann et al.
patent: 2005/0148501 (2005-07-01), Palmer et al.
patent: 2005/0159414 (2005-07-01), Nickolaus et al.
patent: 2005/0165010 (2005-07-01), Nickolaus et al.
patent: 2006/0004014 (2006-01-01), Hoffmann et al.
patent: 2006/0009457 (2006-01-01), Hoffmann et al.
patent: 2006/0025411 (2006-02-01), Hoffmann et al.
patent: 2006/0035902 (2006-02-01), Linz et al.
patent: 2006/0035903 (2006-02-01), Mohr et al.
patent: 2006/0046989 (2006-03-01), Grauert et al.
patent: 2006/0047118 (2006-03-01), Stadtmueller et al.
patent: 2006/0052383 (2006-03-01), Grauert et al.
patent: 2006/0058311 (2006-03-01), Munzert et al.
patent: 2006/0074088 (2006-04-01), Munzert et al.
patent: 2006/0079503 (2006-04-01), Schwede et al.
patent: 2008/0108812 (2008-05-01), Grauert et al.
patent: 2008/0113992 (2008-05-01), Grauert et al.
patent: 2008/0171747 (2008-07-01), Hoffman et al.
patent: 2008/0177066 (2008-07-01), Linz et al.
patent: 2008/0194818 (2008-08-01), Grauert et al.
patent: 2008/0293944 (2008-11-01), Hoffmann et al.
patent: 2009/0143379 (2009-06-01), Mohr et al.
patent: WO 01/19825 (2001-03-01), None
patent: WO 02/076954 (2002-10-01), None
patent: WO 02/076985 (2002-10-01), None
patent: WO 03/020722 (2003-03-01), None
patent: WO 2004/076454 (2004-09-01), None
Dorwald F. A. Side Reactions in Organic Synthesis, 2005, Wiley: VCH, Weinheim p. IX of Preface.
Vippagunta et. al. Advanced Drug Delivery Reviews 48 (2001) 3-26.
Tenbrink, R. E. et al., “Antagonist, partial agonist, and full agonist imidazo[1,5-a]quinoxaline amides and carbamates acting through the BABA/Benzodiazepine receptor”. J. Med. Chem. 1994, 37, pp. 758-768.
Turner, W.W.et al., “Recent advances in the medicinal chemistry of antifungal agents”. Current Pharmacutical Design, 1996, 2, pp. 209-224.
Verschuren, E.W. et al., “The cell cycle and how it is steered by Kaposi's sarcoma-associated herpesvirus cyclin”. Journal of General Virology, 2004, 85, pp. 1347-1361.
Viral Defense Foundation. www.viraldefense.org/mission.htm, downloaded Mar. 26, 2009.
Visiting Nurse Association of America. www.vnaa.org/gen/Germ—Protection—Center—Cold—and—Flu—Resources,html, downloaded Mar. 26, 2009.
Voskoglou-Nomikos, T. et al., “Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models”. Clinical Cancer Research vol. 9, 2003, pp. 4227-4239.
Webster's Comprehensive Dictionary, 1996, pp. 1013-1014 .
Wolf, D. E.et al., “The structure of rhizopterin”. Contribution from the Research Labs of Merck and Co. Inc. Nov. 1947, Journal of American Chem. Soc., vol. 69, pp. 2753-2759. XP002352205.
Ghandi, L, et al., “An Open-Label Phase II Trial of the PLK Inhibitor BI 2536 in Patients with Sensitive Relapse Small Cell Lung Cancer”. ASCO Meeting 2009.
Wagner, B. et al, “7-Benzylamino-6-chloro-2-piperazino-4-pyrrolidino-pteridine, a potent inhibitor of cAMP-specific phosphodiesterase, enhancing nuclear protein binding to the CRE consensus sequence in human tumour cells”, Biochemical Pharmacology, Pergamon, Oxford, GB, 2002, pp. 659-668.
Wagner, G. et al., “Synthesis of new pluido[3',2':4,5] thieno '3,2-d] 1,2,3-triazine derivatives as antianaphylactics”. Biosciences Dept of the University of Leipzig, Pharmazie (Pharmacy), 48, vol. 7, 1993, pp. 514-518.
Wikipedia. “Melting Point”, Jan 17, 2007.
Brandl Trixi
Grauert Matthias
Hauptmann Rudolf
Hoffmann Matthias
Steegmaier Martin
Boehringer Ingelheim International GmbH
Bottino Anthony P.
Devlin Mary-Ellen M.
Morris Michael P.
Murray Jeffrey H
LandOfFree
Pyridodihydropyraziones, process for their manufacture and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyridodihydropyraziones, process for their manufacture and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyridodihydropyraziones, process for their manufacture and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4092599